These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7678870)

  • 1. Maximum urinary flow rate by uroflowmetry: automatic or visual interpretation.
    Grino PB; Bruskewitz R; Blaivas JG; Siroky MB; Andersen JT; Cook T; Stoner E
    J Urol; 1993 Feb; 149(2):339-41. PubMed ID: 7678870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
    Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
    N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia.
    Tammela TL; Kontturi MJ
    J Urol; 1993 Feb; 149(2):342-4. PubMed ID: 7678871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study.
    Kirby RS; Vale J; Bryan J; Holmes K; Webb JA
    Eur Urol; 1993; 24(1):20-6. PubMed ID: 7689971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Finasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation.
    Kirby RS; Bryan J; Eardley I; Christmas TJ; Liu S; Holmes SA; Vale JA; Shanmuganathan K; Webb JA
    Br J Urol; 1992 Jul; 70(1):65-72. PubMed ID: 1379107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group.
    Stoner E
    J Urol; 1992 May; 147(5):1298-302. PubMed ID: 1373779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia.
    Beisland HO; Binkowitz B; Brekkan E; Ekman P; Kontturi M; Lehtonen T; Lundmo P; Pappas F; Round E; Shapiro D
    Eur Urol; 1992; 22(4):271-7. PubMed ID: 1283370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of finasteride in men with benign prostatic hyperplasia.
    Walsh PC
    J Urol; 1993 Apr; 149(4):932-3. PubMed ID: 7681121
    [No Abstract]   [Full Text] [Related]  

  • 9. Improvement of pressure flow parameters with finasteride is greater in men with large prostates. Finasteride Urodynamics Study Group.
    Abrams P; Schäfer W; Tammela TL; Barrett DM; Hedlund H; Rollema HJ; Matos-Ferreira A; Nordling J; Bruskewitz R; Andersen JT; Hald T; Miller P; Kirby R; Mustonen S; Cannon A; Jacobsen CA; Gormley GJ; Malice MP; Bach MA
    J Urol; 1999 May; 161(5):1513-7. PubMed ID: 10210385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finasteride for benign prostatic hyperplasia.
    DuBeau CE
    N Engl J Med; 1993 Feb; 328(6):443. PubMed ID: 7678439
    [No Abstract]   [Full Text] [Related]  

  • 11. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
    McConnell JD; Wilson JD; George FW; Geller J; Pappas F; Stoner E
    J Clin Endocrinol Metab; 1992 Mar; 74(3):505-8. PubMed ID: 1371291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year experience in the treatment of benign prostatic hyperplasia with finasteride. The MK-906 (Finasteride) Study Group.
    J Androl; 1991; 12(6):372-5. PubMed ID: 1722792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reproducibility of uroflow measurement: experience during a double-blind, placebo-controlled study of doxazosin in benign prostatic hyperplasia.
    Feneley MR; Dunsmuir WD; Pearce J; Kirby RS
    Urology; 1996 May; 47(5):658-63. PubMed ID: 8650862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Finasteride for benign prostatic hyperplasia.
    Holdcroft C
    Nurse Pract; 1993 Mar; 18(3):57-8. PubMed ID: 7681553
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
    Nickel JC; Gilling P; Tammela TL; Morrill B; Wilson TH; Rittmaster RS
    BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled trial.
    Yu HJ; Chiu TY; Lai MK
    J Formos Med Assoc; 1995; 94(1-2):37-41. PubMed ID: 7542109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Finasteride for benign prostatic hyperplasia.
    Hasinski S; Miller JL; Rose LI
    Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computerized artifact detection and correction of uroflow curves: towards a more consistent quantitative assessment of maximum flow.
    Witjes WP; de la Rosette JJ; Zerbib M; Vignoli GC; Geffriaud C; Debruyne FM; Wijkstra H
    Eur Urol; 1998; 33(1):54-63. PubMed ID: 9471041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New medication for the treatment of benign prostatic hyperplasia.
    Miller CA
    Geriatr Nurs; 1993; 14(2):111-2. PubMed ID: 7681420
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Roehrborn CG; Chapple C; Oelke M; Cox D; Esler A; Viktrup L
    J Urol; 2014 Apr; 191(4):1045-50. PubMed ID: 24445278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.